banner technology

Scientific Publications

1. Falkenberg FW, Krup OC. Compositions and methods for treatment of tumors and metastatic diseases. 2002 Jun 18; 1–57. Patent

2. Grille S, Brugnini A, Nese M, Corley E, Falkenberg FW, Lens D, Chabalgoity JA. A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells. Cancer Immunol Immunother. Springer-Verlag; 2010 Apr;59(4):519–27.

3. Price SA, Davies D, Rowlinson R, Copley CG, Roche A, Falkenberg FW, Riccardi D, Betton GR. Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol Pathol. SAGE Publications; 2010 Apr;38(3):346–58.

4. Krup OC, Kroll I, Böse G, Falkenberg FW. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother. 1999 Nov;22(6):525–38.

5. Labarthe M-C, Halanek N, Birchall L, Russell N, Desel C, Todryk S, Peters MJ, Lucas A, Falkenberg FW, Dalgleish AG, Whelan M, Ward SJ. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother. Springer-Verlag; 2006 Mar;55(3):277–88.

Latest news

showCyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

This email address is being protected from spambots. You need JavaScript enabled to view it.